Contact us
Appointment
Appointment

Sanofi EFC17919 – Relapsing Multiple Sclerosis (RMS)

This clinical research study is evaluating an investigational study drug for individuals living with relapsing multiple sclerosis (RMS). The study places special focus on African American women, who may experience more aggressive MS symptoms and are historically underrepresented in clinical research.

Relapsing Multiple Sclerosis (RMS)
Research Study

By participating, you can help advance MS research and contribute to the development of future treatment options tailored to diverse patient populations.

Frequently Asked Questions

Who May Be Eligible to Participate?

Participants may qualify if they:
  • Are between 18 and 55 years of age
  • Have been diagnosed within the past 2 years with:
  • Relapsing MS
  • Clinically Isolated Syndrome (CIS)
  • Radiologically Isolated Syndrome (RIS)
  • Are not pregnant and are not planning to become pregnant until after the final study injection visit
Additional eligibility criteria will be reviewed with you by the study team.
Relapsing multiple sclerosis is a form of MS marked by periods of new or worsening symptoms, called relapses, followed by times of partial or full recovery. Symptoms and severity can vary from person to person.
Research shows that African American women may experience more aggressive MS symptoms, yet they are underrepresented in clinical trials. This study aims to better understand how new treatments work in this population and help improve future MS care for everyone.
Participants receive study-related care from a specialized medical research team and attend scheduled visits for evaluations and treatment. The study team will explain all procedures, timelines, and requirements before enrollment begins.

Accessibility Toolbar